Healthcare - Articles
Todays Headlines from across the DailyUpdates network (July 7th, 2006) - In today's edition we highlight Biomarin's development of the novel antihypertensive 6R-BH4 and new research describing a promising molecular target for future sepsis therapeutics.
Todays Headlines from across the DailyUpdates network (July 7th, 2006) - In today's edition we highlight Biomarin's development of the novel antihypertensive 6R-BH4 and new research describing a promising molecular target for future sepsis therapeutics. Summaries of this content can be seen below or click here for today's edition of DailyUpdates Breaking News (from DailyUpdates-Cardiovascular Diseases): Biomarin advance novel antihypertensive: Effective blood pressure control for all hypertensive patients remains an elusive goal. Th…
Todays Headlines from across the DailyUpdates network (July 7th, 2006) - In today's edition we highlight Biomarin's development of the novel antihypertensive 6R-BH4 and new research describing a promising molecular target for future sepsis therapeutics. Summaries of this content can be seen below or click here for today's edition of DailyUpdates Breaking News (from DailyUpdates-Cardiovascular Diseases): Biomarin advance novel antihypertensive: Effective blood pressure control for all hypertensive patients remains an elusive goal. Th…
Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, ABIO 08/01. In addition we feature a review describing a potentially groundbreaking drug delivery technology. This technology harnesses protein transduction domains (PTDs), endogenous peptide sequences
Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, AB…
Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, AB…
27-Aug-2010
A recent Department of Health study showed that healthcare associated infection (HCAI) affects 8 per cent of acute admissions to hospitals. These infections can delay discharge home by up to 11 days. For the NHS in England this represents a loss of 3.6 million bed days, with a projected cost of £1 billion a year.
Maureen Bott, Product and Development Manager, Kalamazoo Security Print, comments on the MRSA and solutions to combat the spread of it. “A recent Department of Health study showed that healthcare associated infection (HCAI) affects 8 per cent of acute admissions to hospitals. These infections can delay discharge home by up to 11 days. For the NHS in this represents a loss of 3.6 million bed days, with a projected cost of £1 billion a year. It is well documented that transmission…
Maureen Bott, Product and Development Manager, Kalamazoo Security Print, comments on the MRSA and solutions to combat the spread of it. “A recent Department of Health study showed that healthcare associated infection (HCAI) affects 8 per cent of acute admissions to hospitals. These infections can delay discharge home by up to 11 days. For the NHS in this represents a loss of 3.6 million bed days, with a projected cost of £1 billion a year. It is well documented that transmission…
27-Aug-2010
The leading pharmaceutical companies have historically focused on developing small molecules to drive their bottom line growth. However, this is set to change, with around 60% of revenue growth for 'Big Pharma' companies forecast to come from biologic products. In fact by 2010, annual sales of biologics will have increased by $26 billion, compared to a $13 billion increase for small molecules.
The leading pharmaceutical companies have historically focused on developing small molecules to drive their bottom line growth. However, this is set to change, with around 60% of revenue growth for 'Big Pharma' companies forecast to come from biologic products. In fact by 2010, annual sales of biologics will have increased by $26 billion, compared to a $13 billion increase for small molecules. Datamo…
The leading pharmaceutical companies have historically focused on developing small molecules to drive their bottom line growth. However, this is set to change, with around 60% of revenue growth for 'Big Pharma' companies forecast to come from biologic products. In fact by 2010, annual sales of biologics will have increased by $26 billion, compared to a $13 billion increase for small molecules. Datamo…
Todays Headlines from across the DailyUpdates network - Today we feature news from Vasogen on their candidate treatment of chronic heart failure plus new data from Johnson & Johnson on a new integrin antagonist that may underly a future treatment of asthma
Todays Headlines from across the DailyUpdates network (June 27th) Breaking News (from DailyUpdates-Cardiovascular Disease): New phase III data on heart failure candidate, Velacade: There is a clear need for new treatments for heart failure, as associated mortality and morbidity rates are high. Nearly 5 million Americans and 6.5 million Europeans have heart failure and each year, in the alone, 550,000 new cases of heart failure are diagnosed and nearly 300,000 deaths are registered. The five-year survival rate for patients with heart fail…
Todays Headlines from across the DailyUpdates network (June 27th) Breaking News (from DailyUpdates-Cardiovascular Disease): New phase III data on heart failure candidate, Velacade: There is a clear need for new treatments for heart failure, as associated mortality and morbidity rates are high. Nearly 5 million Americans and 6.5 million Europeans have heart failure and each year, in the alone, 550,000 new cases of heart failure are diagnosed and nearly 300,000 deaths are registered. The five-year survival rate for patients with heart fail…
While the number of individuals with major depressive disorder (MDD) is set to grow only minimally in next two decades, the condition still represents a key health risk, for both society and the individual. For example, MDD is a leading cause of disability and under-diagnosis remains a problem. Furthermore, the leading classes of MDD drugs have been linked to increased suicidality.
It's estimated that 34 million people suffer from MDD in the western world, but new research estimates that the number of individuals with MDD will grow only minimally in the next two decades, to 37 million by 2025. Unlike a number of other global health issues such as cancer and Parkinson's disease, the aging nature of the world's population won't significantly increase the number of those suffering from MDD.…
It's estimated that 34 million people suffer from MDD in the western world, but new research estimates that the number of individuals with MDD will grow only minimally in the next two decades, to 37 million by 2025. Unlike a number of other global health issues such as cancer and Parkinson's disease, the aging nature of the world's population won't significantly increase the number of those suffering from MDD.…
Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate
Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate - to view today's bulletin in its entirety click here or read on for further information on these two publications Breaking News (from DailyUpdates-Oncology): ArQule moves forward with their cell cycle modulator The cell cycle and check-points within the cycle represent a major focus of drug development companies attempting to introduce new cancer therapeutics. One group of molecular targets…
Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate - to view today's bulletin in its entirety click here or read on for further information on these two publications Breaking News (from DailyUpdates-Oncology): ArQule moves forward with their cell cycle modulator The cell cycle and check-points within the cycle represent a major focus of drug development companies attempting to introduce new cancer therapeutics. One group of molecular targets…
Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL
Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL plus today's featured jobs. To see the entire bulletin click here Breaking News (from DailyUpdates-Cancer Immunotherapy): Micromet develops new lymphoma thera…
Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL plus today's featured jobs. To see the entire bulletin click here Breaking News (from DailyUpdates-Cancer Immunotherapy): Micromet develops new lymphoma thera…
In today's edition of DailyUpdates we report on CD40:CD40L. Traditionally a target for autoimmune/transplant therapeutics, we highlight a study supporting the development of blockers of CD40:CD40L as candidate treatments of Alzheimer's disease. We also highlight a new oncology candidate in development by Lorus
Todays Headlines from across the DailyUpdates network. In today's edition (see it in full) we report on CD40:CD40L. Traditionally a target for autoimmune/transplant therapeutics, we highlight a study supporting the development of blockers of CD40:CD40L as candidate treatments of Alzheimer's disease. We also highlight a new oncology candidate in development by Lorus Breaking News (from DailyUpdates-Oncology): Locus Pharmaceuticals about to enter the clinic with novel cell cycle r…
Todays Headlines from across the DailyUpdates network. In today's edition (see it in full) we report on CD40:CD40L. Traditionally a target for autoimmune/transplant therapeutics, we highlight a study supporting the development of blockers of CD40:CD40L as candidate treatments of Alzheimer's disease. We also highlight a new oncology candidate in development by Lorus Breaking News (from DailyUpdates-Oncology): Locus Pharmaceuticals about to enter the clinic with novel cell cycle r…
Cell Therapeutics has announced positive phase III data for Xyotax in non-small cell lung cancer, with the drug significantly increasing survival in pre-menopausal female patients with high estrogen levels. However, with such a limited patient population, Xyotax will struggle to compete with Sanofi-Aventis' Taxotere, Eli Lilly's Gemzar and genericized paclitaxel in cost-constrained markets.
Cell Therapeutics has announced positive phase III data for Xyotax in non-small cell lung cancer, with the drug significantly increasing survival in pre-menopausal female patients with high estrogen levels. However, with such a limited patient population, Xyotax will struggle to compete with Sanofi-Aventis' Taxotere, Eli Lilly's Gemzar and genericized paclitaxel in cost-constrained markets. Xyotax (pa…
Cell Therapeutics has announced positive phase III data for Xyotax in non-small cell lung cancer, with the drug significantly increasing survival in pre-menopausal female patients with high estrogen levels. However, with such a limited patient population, Xyotax will struggle to compete with Sanofi-Aventis' Taxotere, Eli Lilly's Gemzar and genericized paclitaxel in cost-constrained markets. Xyotax (pa…
In today's edition of DailyUpdates we headline with news from CuraGen and TopoTarget on a new trial evaluating the combination of an HDAC inhibitor an cis-retinoid acid. In addition we highlight research from Wyeth suggesting a new approach to depression
Todays Headlines from across the DailyUpdates network (access DailyUpdates 15th June, 2006 here) Breaking News (from DailyUpdates-Oncology): CuraGen and TopoTarget to test the promising combination of HDAC inhibition and retinoic acid receptor activation in patients with solid tumors The histone deacetylase inhibitor class of therapeutics represents a highly exciting approach to cancer. Merck's ZOLINZA (SAHA; vorinostat) and Gloucester Pharmaceuticals' Depsipeptide (FK228) lead this class however . Both candidates are evaluated in our fea…
Todays Headlines from across the DailyUpdates network (access DailyUpdates 15th June, 2006 here) Breaking News (from DailyUpdates-Oncology): CuraGen and TopoTarget to test the promising combination of HDAC inhibition and retinoic acid receptor activation in patients with solid tumors The histone deacetylase inhibitor class of therapeutics represents a highly exciting approach to cancer. Merck's ZOLINZA (SAHA; vorinostat) and Gloucester Pharmaceuticals' Depsipeptide (FK228) lead this class however . Both candidates are evaluated in our fea…
Data presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta this month suggest that administering the epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab) fortnightly rather than weekly in metastatic colorectal cancer (mCRC) is a feasible option. Another study probing whether scaling up the dose, to the point where patients experience the significant rash linked to long survival, achieves a better response, shows high doses are well tolerated.
Administering treatment in community oncology units achieves results that match those of specialist centres, according to the MABEL study; and phase III trials in the US and Europe are now focusing on investigating Erbitux as a first-line therapy option for mCRC. Fortnightly regimen could make life eas…
Administering treatment in community oncology units achieves results that match those of specialist centres, according to the MABEL study; and phase III trials in the US and Europe are now focusing on investigating Erbitux as a first-line therapy option for mCRC. Fortnightly regimen could make life eas…
Today's edition highlights news from Metabolex announcing the initiation of a Phase 2/3 trial of a novel insulin sensitizer, metaglidasen. In addition we discuss research published by Advanced Life Sciences who are making exciting breakthroughs moving towards the treatment of HIV Tuberculosis co-infection which has become a global catastrophe.
Todays Headlines from across the DailyUpdates network (June 12th, 2006 - access this edition) Breaking News (from DailyUpdates-Metabolic Disorders): Metabolex announce phase II/III trial of novel insulin sensitizer Diabetes affects approximately 170 million people worldwide a figure that is increasing with the WHO predicting 300 million diabetics by 2025 (see The World Diabetes Market, 2005-2011). The alone has 20.8 million people suffering with dia…
Todays Headlines from across the DailyUpdates network (June 12th, 2006 - access this edition) Breaking News (from DailyUpdates-Metabolic Disorders): Metabolex announce phase II/III trial of novel insulin sensitizer Diabetes affects approximately 170 million people worldwide a figure that is increasing with the WHO predicting 300 million diabetics by 2025 (see The World Diabetes Market, 2005-2011). The alone has 20.8 million people suffering with dia…
Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects for the future. With the FDA approval and commercialization of Velcade, scientists are now beginning to see the potential of this ever expanding science. New therapeutic targets are being explored and implica
Welcome! Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects…
Welcome! Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects…
Today we report on the FDA approval of Merck's HPV vaccine, the first such vaccine to be approved in the US; and a candidate treatment for various cardiovascular diseases
Todays Headlines from across the DailyUpdates network (9th June 2006) Breaking News (from DailyUpdates-Infectious Diseases): Merck wins the race for HPV vaccine approval in the US HPV is the most commonly diagnosed viral sexually transmitted disease in the and , with conservative annual incidence estimates of 5.5 million in the alone. Over 100 types of HPV, causing a variety of diseases, have been identified. It is believed that 50-75% of HPV infections involve high-risk HPV types, leading to approximately 500,000 new cases of cervical cancer and 232,000 deaths worldwide each year. Treatment options are limited, with no k…
Todays Headlines from across the DailyUpdates network (9th June 2006) Breaking News (from DailyUpdates-Infectious Diseases): Merck wins the race for HPV vaccine approval in the US HPV is the most commonly diagnosed viral sexually transmitted disease in the and , with conservative annual incidence estimates of 5.5 million in the alone. Over 100 types of HPV, causing a variety of diseases, have been identified. It is believed that 50-75% of HPV infections involve high-risk HPV types, leading to approximately 500,000 new cases of cervical cancer and 232,000 deaths worldwide each year. Treatment options are limited, with no k…
DailyUpdates 31st May: Today's edition of DailyUpdates focuses on a controversial area of neurotransmission: opioids, cannabinoids and their overlap. Our featured press release is from Allon Therapeutics and announces further progress on their novel approach to neurodegenerative disorders. Read on for an overview or visit today's edition of DailyUpdates here
DailyUpdates 31st May: Today's edition of DailyUpdates focuses on a controversial area of neurotransmission: opioids, cannabinoids and their overlap. Our featured press release is from Allon Therapeutics and announces further progress on their novel approach to neurodegenerative disorders. Read on for an overview or visit today's edition of DailyUpdates hereCannabinoids and opioids - their intereaction in the modulation of pain: Canna…
DailyUpdates 31st May: Today's edition of DailyUpdates focuses on a controversial area of neurotransmission: opioids, cannabinoids and their overlap. Our featured press release is from Allon Therapeutics and announces further progress on their novel approach to neurodegenerative disorders. Read on for an overview or visit today's edition of DailyUpdates hereCannabinoids and opioids - their intereaction in the modulation of pain: Canna…
27-Aug-2010
DailyUpdates 2nd June: In today’s edition of DailyUpdates we highlight exciting new data on the potential use of the antihypertensive, losartan as a modulator of insulin release and production and hence a directly acting therapeutic for the treatment of diabetes. This supplements additional beneficial activity resulting from blood pressure control. In addition we report on European approval of Thelin, Encysive’s candidate for the treatment of pulmonary hypertension
DailyUpdates 2nd June: In today’s edition of DailyUpdates we highlight exciting new data on the potential use of the antihypertensive, losartan as a modulator of insulin release and production and hence a directly acting therapeutic for the treatment of diabetes. This supplements additional beneficial activity resulting from bloo…
DailyUpdates 2nd June: In today’s edition of DailyUpdates we highlight exciting new data on the potential use of the antihypertensive, losartan as a modulator of insulin release and production and hence a directly acting therapeutic for the treatment of diabetes. This supplements additional beneficial activity resulting from bloo…
27-Aug-2010
Osteoarthritis is the leading cause of disability in the US, and is estimated to be the eighth most common cause of disability worldwide, with around 89 million adults in the seven major markets having a form of symptomatic osteoarthritis. OA therefore offers an attractive commercial target. However, relatively low disease awareness and Cox-2s controversy have curbed the market's potential so far.
Osteoarthritis (OA) is a degeneration of the joints characterized by progressive destruction of articular cartilage and articular structures. It is a complex process that involves multiple changes in joint structure and, according to Datamonitor estimates, affects 89 million adults in the seven major pharmaceutical markets. Due to the current widespread nature of the condition, the World Health…
Osteoarthritis (OA) is a degeneration of the joints characterized by progressive destruction of articular cartilage and articular structures. It is a complex process that involves multiple changes in joint structure and, according to Datamonitor estimates, affects 89 million adults in the seven major pharmaceutical markets. Due to the current widespread nature of the condition, the World Health…
DailyUpdates 6th June: As ASCO continues in full swing, we again focus on oncology. Today's edition of DailyUpdates includes 10 new papers on oncology research plus a further 20 or so press releases from companies presenting at ASCO. This is of course in addition to the rest of our content from across the drug development sector (see it all here). Today's headline paper unerpins the intriguing idea that the premedication required prior to Taxotere administration may significantly limit its effic
DailyUpdates 6th June: As ASCO continues in full swing, we again focus on oncology. Today's edition of DailyUpdates includes 10 new papers on oncology research plus a further 20 or so press releases from companies presenting at ASCO. This is of course in addition to the rest of our content from acro…
DailyUpdates 6th June: As ASCO continues in full swing, we again focus on oncology. Today's edition of DailyUpdates includes 10 new papers on oncology research plus a further 20 or so press releases from companies presenting at ASCO. This is of course in addition to the rest of our content from acro…
(The American Society of Clinical Oncology) now in full swing, cancer is not surprisingly the focus of today's news section and out of the 20 or so press releases featured we highlight and announcement by Cell Genesys describing the development of their GVAX vaccine for the treatment of CML. In their phase 2 trial the company reports that a complete molecular response is seen in 25% of patients whose treatment included GVAX - this compares to historical data of about 10% in patients not receivin
DailyUpdates 5th June, 2006: With ASCO (The American Society of Clinical Oncology) now in full swing, cancer is not surprisingly the focus of today's news section and out of the 20 or so press releases featured we highlight and announcement by Cell Genesys describing the development of their GVAX v…
DailyUpdates 5th June, 2006: With ASCO (The American Society of Clinical Oncology) now in full swing, cancer is not surprisingly the focus of today's news section and out of the 20 or so press releases featured we highlight and announcement by Cell Genesys describing the development of their GVAX v…
